The 8th B2B Uro-Oncology: GU Cancers Triad Meeting will feature the latest innovations, multidisciplinary practices, scientific advances, and contemporary discussions with respect to the evolving management of bladder, kidney, and prostate cancers. Mark your calendar on November 13, 2026, for this unique meeting, held in conjunction with the 46th SIU Annual Congress in Florence, Italy. Access to the B2B programme is included in your SIU 2026 registration.

About the B2B Uro-Oncology: GU Cancers Triad  

The rapidly evolving landscape of GU cancers presents significant challenges for specialists across urology, medical oncology, and radiation oncology. As new data emerge, clinicians are required to stay current with the latest developments to ensure the highest standard of care for their patients.

Join the prestigious B2B Scientific Programme Committee and global thought leaders to stay current with the latest advances and evidence-based practices in GU cancers. In this all-day programme, the multidisciplinary faculty will review updates on diagnosis and treatment of prostate, bladder, and kidney cancers, discuss applications of new therapeutic strategies and surgical skills into clinical practice, and provide guidance for improving patient-centered care.

Learning Objectives:

• Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
• Recognize the role of imaging and genetic markers in guiding treatment decision-making.
• Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
• Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
• Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.